NCI’s Evolving Clinical Trials System

James H. Doroshow, M.D.
Deputy Director for Clinical and Translational Research
National Cancer Institute, NIH

Mack Roach III M.D., FOCR
Professor of Radiation Oncology and Urology
Chair Department of Radiation Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

National Cancer Advisory Board
Bethesda, MD
September 9, 2014
Emphasized critical need for a public clinical trials system

NCI has taken a comprehensive approach to transforming its clinical trials system to create a highly integrated network that can address rapid advances in cancer biology based on:

- Reports from Clinical Trials & Operational Efficiency Working Groups
- Recommendations from the IOM Report
• Advances in cancer biology offer enormous potential to improve clinical oncologic practice

• Opportunity to move beyond cytotoxic treatments to more effective therapies targeting the specific characteristics of a patient’s tumor

• Challenge of evaluating an ever-increasing number of new, highly specific agents in molecularly-defined subsets of patients
Goals for Restructuring: 2005

• Coordination
  - Coordinate clinical trials research through data sharing database and providing incentives for collaboration as a network

• Prioritization/Scientific Quality
  - Stakeholders design and prioritize clinical trials that address the most important questions, using the tools of modern cancer biology

• Standardization
  - Standardize IT infrastructure and clinical research tools

• Operational Efficiency
  - Use resources most efficiently through improved cost-effectiveness, accrual rates, and more rapid trial initiation

• Integrated Management
  - Restructure extramural and intramural oversight of NCI clinical trials
Program for Today

**NCI’s Evolving Clinical Trials System**

Overview: Drs. Mack Roach & James Doroshow  
Clinical Trials Network: Dr. Margaret Mooney  
Community Oncology Research Program: Dr. Worta McCaskill-Stevens  
Experimental Therapeutics Clinical Trials Network: Dr. Percy Ivy  
Clinical Trials Tissue Banks: Dr. Irena Lubensky  
Questions: Dr. Jeff Abrams

**Impact of the New System**

Clinical Trials Network Chair: Dr. Wally Curran  
Lead Academic Site/Cancer Center Perspective: Dr. Nancy Davidson  
Disease Steering Committee Chair Perspective: Dr. Drew Ridge  
Community Oncology Research Program PI: Dr. Augusto Ochoa  
Early Phase Therapy/Translational Scientist: Dr. Geoffrey Shapiro  
Patient Advocate: Nancy Roach  
Discussion: Drs. Mack Roach and James Doroshow